NASDAQ:CLLSCellectis Stock Price, Forecast & News

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLLS shares have increased by 48.0% and is now trading at $16.92. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cellectis.

Cellectis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cellectis.

Cellectis SA (NASDAQ:CLLS) announced its earnings results on Wednesday, May, 6th. The biotechnology company reported $0.47 EPS for the quarter, beating the consensus estimate of ($0.59) by $1.06. The biotechnology company had revenue of $51.91 million for the quarter, compared to the consensus estimate of $21.07 million. Cellectis had a negative net margin of 93.27% and a negative return on equity of 17.60%. View Cellectis' earnings history.

7 brokers have issued 12 month target prices for Cellectis' shares. Their forecasts range from $11.00 to $73.00. On average, they anticipate Cellectis' stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price. View analysts' price targets for Cellectis.

News stories about CLLS stock have trended somewhat negative on Saturday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cellectis earned a news impact score of -1.8 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Cellectis.

Cellectis saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 256,900 shares, a decrease of 16.9% from the June 15th total of 309,200 shares. Based on an average daily trading volume, of 208,700 shares, the short-interest ratio is currently 1.2 days. Currently, 0.6% of the shares of the stock are short sold. View Cellectis' Current Options Chain.

Some companies that are related to Cellectis include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT), Editas Medicine (EDIT), Alector (ALEC), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Bill.com (RVMD), Sorrento Therapeutics (SRNE), Beam Therapeutics (BEAM), Sangamo Therapeutics (SGMO), Mesoblast (MESO), Regenxbio (RGNX) and Legend Biotech (PCVX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Micron Technology (MU), Intellia Therapeutics (NTLA), Sarepta Therapeutics (SRPT) and Alibaba Group (BABA).

(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by a number of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.16%).

CLLS stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc..

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $16.92.

Cellectis has a market capitalization of $718.59 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe.

The official website for Cellectis is www.cellectis.com.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]